In their publication, they provide evidence for their position that "the safety of aluminium-based vaccine adjuvants, like that of any environmental factor presenting a risk of neurotoxicity and to which the young child is exposed, must be seriously evaluated without further delay, particularly at a time when the CDC is announcing a still increasing prevalence of autism spectrum disorders, of 1 child in 54 in the USA."

The publication goes on to address concerns it has with another paper that was published a year prior, emphasizing that the authors of that specific publication, JP Goullé & L Grangeot-Keros,

Described general knowledge on aluminum (Al) exposure, kinetics and toxicity but made very little effort to delineate the scientific questions specifically related to Al adjuvants in vaccines. Instead of representing the bulk of their review, the subject of Al adjuvants covered no more than one third of the 3 page-text. Numerous important papers on the topic were omitted, i.e. 20 years of scientific publications in clinical, post-mortem, in vitro and in vivo experimental studies published by independent research teams, worldwide experts in this topic, were simply omitted.